In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients.
Fanconi anemia (FA) is a rare inherited genomic instability syndrome representing one of the best examples of hematopoietic stem cell deficiency. Although FA might be an excellent candidate for bone marrow (BM) genetic correction ex vivo, knockout animal models are not sufficient to guide preclinical steps, and gene therapy attempts have proven disappointing so far. Contributing to these poor results is a characteristic and dramatic early BM-cells die-off when placed in culture. We show here that human primary FA BM cell survival can be ameliorated by using specific culture conditions that limit oxidative stress. When coupled with retrovirus-mediated transfer of the main complementation group FANCA-cDNA, we could achieve long-term reconstitution of the stem cell compartment both in vitro and in vivo. Gene-corrected BM cultures grew for >120 days, and after cultured cell transplantation into NOD/SCID mice, clonogenic human cells carrying the FANCA transgene could be detected 6 months after transduction. By comparison, untransduced cells died in culture by 15 days. Of necessity for ethical reasons, experiments were conducted on a very limited number of primary BM cells. By using low cytokine regimen and conditions matching regulatory requirements, a contingent of gene-corrected cells slowly emerges with an unmet potential for in vivo engraftment. Future therapeutic applications of stem cells might be expanding from these data. In addition, we provide a model of gene-corrected human primary cell growth that carries the potential to better delineate the combined role of both DNA damage and oxidative stress in the pathogenesis of FA.
Cohen-Haguenauer
Odile
O
Laboratory of Biotechnology and Applied Pharmacogenetics, Ecole Normale Supérieure de Cachan, 94235 Cachan Cedex, France. odile.haguenauer@lbpa.ens-cachan.fr
Péault
Bruno
B
Bauche
Cécile
C
Daniel
Marie-Thérèse
MT
Casal
Ibrahim
I
Levy
Vincent
V
Dausset
Jean
J
Boiron
Michel
M
Auclair
Christian
C
Gluckman
Eliane
E
Marty
Michel
M
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology / Q000502:physiology*; D016026:Bone Marrow Transplantation; D002648:Child; D018076:DNA, Complementary / Q000235:genetics; D005199:Fanconi Anemia / Q000235:genetics / Q000628:therapy*; D052217:Fanconi Anemia Complementation Group A Protein / Q000235:genetics*; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D018384:Oxidative Stress / Q000187:drug effects; D014162:Transfection
D000975:Antioxidants; D018076:DNA, Complementary; C498471:FANCA protein, human; D052217:Fanconi Anemia Complementation Group A Protein